

Allison A Eddy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4100551/publications.pdf>

Version: 2024-02-01

93
papers

7,459
citations

76326

40
h-index

53230

85
g-index

96
all docs

96
docs citations

96
times ranked

7376
citing authors

#	ARTICLE	IF	CITATIONS
1	Child and caregiver perspectives on access to psychosocial and educational support in pediatric chronic kidney disease: a focus group study. <i>Pediatric Nephrology</i> , 2023, 38, 249-260.	1.7	2
2	Patient and caregiver perspectives on blood pressure in children with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1330-1339.	0.7	2
3	Perspectives of Clinicians on Shared Decision Making in Pediatric CKD: A Qualitative Study. <i>American Journal of Kidney Diseases</i> , 2022, 80, 241-250.	1.9	3
4	Impact of training nephrologists from developing nations and strategies for sustaining a training program in its fourth decade. <i>Kidney International</i> , 2021, 99, 1073-1076.	5.2	7
5	Drug-induced tubulointerstitial nephritis: hypersensitivity and necroinflammatory pathways. <i>Pediatric Nephrology</i> , 2020, 35, 547-554.	1.7	17
6	Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrologyâ€”Children and Adolescents (SONG-KIDS) consensus workshops. <i>Kidney International</i> , 2020, 98, 553-565.	5.2	58
7	Developing Consensus-Based Outcome Domains for Trials in Children and Adolescents With CKD: An International Delphi Survey. <i>American Journal of Kidney Diseases</i> , 2020, 76, 533-545.	1.9	19
8	Identifying Important Outcomes for Young People With CKD and Their Caregivers: A Nominal Group Technique Study. <i>American Journal of Kidney Diseases</i> , 2019, 74, 82-94.	1.9	42
9	Uromodulin deficiency alters tubular injury and interstitial inflammation but not fibrosis in experimental obstructive nephropathy. <i>Physiological Reports</i> , 2018, 6, e13654.	1.7	17
10	Child and Parental Perspectives on Communication and Decision Making in Pediatric CKD: A Focus Group Study. <i>American Journal of Kidney Diseases</i> , 2018, 72, 547-559.	1.9	46
11	Range and Heterogeneity of Outcomes in Randomized Trials of Pediatric Chronic Kidney Disease. <i>Journal of Pediatrics</i> , 2017, 186, 110-117.e11.	1.8	35
12	Setting New Directions for Research in Childhood Nephrotic Syndrome: Results From a National Workshop. <i>Canadian Journal of Kidney Health and Disease</i> , 2017, 4, 205435811770338.	1.1	6
13	Standardised Outcomes in Nephrologyâ€”Children and Adolescents (SONG-Kids): a protocol for establishing a core outcome set for children with chronic kidney disease. <i>Trials</i> , 2016, 17, 401.	1.6	41
14	Interstitial Nephritis in Children. , 2016, , 1013-1036.		4
15	The impact of small kidneys. <i>Pediatric Nephrology</i> , 2015, 30, 1501-1509.	1.7	14
16	Overview of the cellular and molecular basis of kidney fibrosis. <i>Kidney International Supplements</i> , 2014, 4, 2-8.	14.2	193
17	The Canadian Childhood Nephrotic Syndrome (CHILDNEPH) Project: Overview of Design and Methods. <i>Canadian Journal of Kidney Health and Disease</i> , 2014, 1, 17.	1.1	19
18	Cysteamine Modulates Oxidative Stress and Blocks Myofibroblast Activity in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 43-54.	6.1	58

#	ARTICLE	IF	CITATIONS
19	Acute kidney injury and its association with in-hospital mortality among children with acute infections. <i>Pediatric Nephrology</i> , 2013, 28, 2199-2206.	1.7	39
20	The origin of scar-forming kidney myofibroblasts. <i>Nature Medicine</i> , 2013, 19, 964-966.	30.7	32
21	Mannose Receptor 2 Attenuates Renal Fibrosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 236-251.	6.1	62
22	Critical and Honest Conversations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1664-1672.	4.5	157
23	Vascular Endothelial Cadherin Modulates Renal Interstitial Fibrosis. <i>Nephron Experimental Nephrology</i> , 2012, 120, e20-e31.	2.2	22
24	Albumin-induced apoptosis of glomerular parietal epithelial cells is modulated by extracellular signal-regulated kinase 1/2. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1330-1343.	0.7	32
25	Investigating mechanisms of chronic kidney disease in mouse models. <i>Pediatric Nephrology</i> , 2012, 27, 1233-1247.	1.7	116
26	Scraping fibrosis: UMODulating renal fibrosis. <i>Nature Medicine</i> , 2011, 17, 553-555.	30.7	19
27	Nicotinic acetylcholine receptor $\alpha 1$ promotes calpain-1 activation and macrophage inflammation in hypercholesterolemic nephropathy. <i>Laboratory Investigation</i> , 2011, 91, 106-123.	3.7	16
28	The TGF- $\beta 2$ Route to Renal Fibrosis Is Not Linear: The miR-21 Viaduct. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1573-1575.	6.1	4
29	Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, F1244-F1254.	2.7	14
30	Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, F245-F253.	2.7	72
31	Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group. <i>American Journal of Kidney Diseases</i> , 2010, 55, 50-60.	1.9	73
32	Round 3 at JASN (2001 to 2007): Recollections of the Third Editorial Team. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1409-1410.	6.1	2
33	Serine proteases, inhibitors and receptors in renal fibrosis. <i>Thrombosis and Haemostasis</i> , 2009, 101, 656-664.	3.4	70
34	CD36 Regulates Oxidative Stress and Inflammation in Hypercholesterolemic CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 495-505.	6.1	127
35	Phase I Trial of Rosiglitazone in FSGS. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 39-47.	4.5	34
36	A Novel Signaling Pathway. <i>Journal of Biological Chemistry</i> , 2009, 284, 29050-29064.	3.4	30

#	ARTICLE	IF	CITATIONS
37	Pathophysiology of Progressive Renal Disease. , 2009, , 1631-1659.		4
38	Serine proteases, inhibitors and receptors in renal fibrosis. Thrombosis and Haemostasis, 2009, 101, 656-64.	3.4	41
39	Urokinase and its receptors in chronic kidney disease. Frontiers in Bioscience - Landmark, 2008, Volume, 5462.	3.0	34
40	Macrophage diversity in renal injury and repair. Journal of Clinical Investigation, 2008, 118, 3522-3530.	8.2	637
41	Interstitial Nephritis. , 2008, , 527-538.		0
42	Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. American Journal of Physiology - Renal Physiology, 2007, 293, F575-F585.	2.7	70
43	Plasmin(ogen) Promotes Renal Interstitial Fibrosis by Promoting Epithelial-to-Mesenchymal Transition. Journal of the American Society of Nephrology: JASN, 2007, 18, 846-859.	6.1	97
44	Endogenous urokinase lacks antifibrotic activity during progressive renal injury. American Journal of Physiology - Renal Physiology, 2007, 293, F12-F19.	2.7	40
45	Subepithelial Humps and Microthrombi: Looking for a Mechanism. American Journal of Kidney Diseases, 2006, 47, 365-370.	1.9	1
46	Ramping up endogenous defences against chronic kidney disease. Nephrology Dialysis Transplantation, 2006, 21, 1174-1177.	0.7	9
47	Plasminogen Activator Inhibitor-1 Deficiency Has Renal Benefits but Some Adverse Systemic Consequences in Diabetic Mice. Nephron Experimental Nephrology, 2006, 104, e23-e34.	2.2	31
48	Chronic Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2006, 17, 2964-2966.	6.1	171
49	Plasminogen Activator Inhibitor-1 in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 2999-3012.	6.1	213
50	Multifunctionality of PAI-1 in fibrogenesis: Evidence from obstructive nephropathy in PAI-1 overexpressing mice. Kidney International, 2005, 67, 2221-2238.	5.2	124
51	Can renal fibrosis be reversed?. Pediatric Nephrology, 2005, 20, 1369-1375.	1.7	47
52	Progression in Chronic Kidney Disease. Advances in Chronic Kidney Disease, 2005, 12, 353-365.	1.4	280
53	Exogenous Bone Morphogenetic Protein-7 Fails to Attenuate Renal Fibrosis in Rats with Overload Proteinuria. Nephron Experimental Nephrology, 2004, 97, e123-e135.	2.2	22
54	Mitogenic Signaling of Urokinase Receptor-Deficient Kidney Fibroblasts: Actions of an Alternative Urokinase Receptor and LDL Receptor-Related Protein. Journal of the American Society of Nephrology: JASN, 2004, 15, 2090-2102.	6.1	19

#	ARTICLE	IF	CITATIONS
55	Why is proteinuria an ominous biomarker of progressive kidney disease?. <i>Kidney International</i> , 2004, 66, S76-S89.	5.2	138
56	Expression of nephrin in acquired forms of nephrotic syndrome in childhood. <i>Pediatric Nephrology</i> , 2004, 19, 300-305.	1.7	25
57	The NPHP1 Gene Deletion Associated with Juvenile Nephronophthisis Is Present in a Subset of Individuals with Joubert Syndrome. <i>American Journal of Human Genetics</i> , 2004, 75, 82-91.	6.2	228
58	Proteinuria and interstitial injury. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 277-281.	0.7	134
59	Nephrotic syndrome in childhood. <i>Lancet, The</i> , 2003, 362, 629-639.	13.7	716
60	Urokinase Receptor Modulates Cellular and Angiogenic Responses in Obstructive Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1234-1253.	6.1	57
61	Urokinase Receptor Deficiency Accelerates Renal Fibrosis in Obstructive Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1254-1271.	6.1	111
62	An Introduction to Frontiers in Nephrology. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2185-2185.	6.1	2
63	Plasminogen activator inhibitor-1 and the kidney. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 283, F209-F220.	2.7	166
64	Role of cellular infiltrates in response to proteinuria. <i>American Journal of Kidney Diseases</i> , 2001, 37, S25-S29.	1.9	72
65	Mast cells find their way to the kidney. <i>Kidney International</i> , 2001, 60, 375-377.	5.2	23
66	PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. <i>Kidney International</i> , 2001, 60, 587-596.	5.2	246
67	TIMP-1 Deficiency Does Not Attenuate Interstitial Fibrosis in Obstructive Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 736-748.	6.1	108
68	Interstitial fibrosis in mice with overload proteinuria: Deficiency of TIMP-1 is not protective. <i>Kidney International</i> , 2000, 58, 618-628.	5.2	109
69	Molecular basis of renal fibrosis. <i>Pediatric Nephrology</i> , 2000, 15, 290-301.	1.7	555
70	Renal remodelling in dietary protein modified rat polycystic kidney disease. <i>Pediatric Nephrology</i> , 1999, 13, 567-570.	1.7	12
71	Interstitial fibrosis in hypercholesterolemic rats: Role of oxidation, matrix synthesis, and proteolytic cascades. <i>Kidney International</i> , 1998, 53, 1182-1189.	5.2	59
72	Expression and Function of Monocyte Chemoattractant Protein-1 in Experimental Nephrotic Syndrome. <i>Clinical Immunology and Immunopathology</i> , 1996, 78, 140-151.	2.0	28

#	ARTICLE	IF	CITATIONS
73	Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. <i>Arthritis and Rheumatism</i> , 1996, 39, 671-676.	6.7	73
74	Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia. <i>Kidney International</i> , 1996, 50, 1139-1149.	5.2	100
75	Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. <i>Kidney International</i> , 1995, 47, 1546-1557.	5.2	338
76	Neurologic manifestations of pediatric systemic lupus erythematosus. <i>Pediatric Neurology</i> , 1995, 13, 191-197.	2.1	138
77	Xanthogranulomatous Pyelonephritis in Children. <i>Clinical Pediatrics</i> , 1994, 33, 360-366.	0.8	40
78	The contribution of antibody-mediated cytotoxicity and immune-complex formation to tubulointerstitial disease in passive Heymann nephritis. <i>Clinical Immunology and Immunopathology</i> , 1992, 62, 42-55.	2.0	12
79	Tubulointerstitial nephritis. <i>Pediatric Nephrology</i> , 1992, 6, 572-586.	1.7	37
80	Intrarenal distribution of clusterin following reduction of renal mass. <i>Kidney International</i> , 1992, 41, 938-950.	5.2	36
81	Presence of thyroid abnormalities in children with systemic lupus erythematosus. <i>Journal of Pediatrics</i> , 1991, 119, 277-279.	1.8	38
82	Pulmonary Hemorrhage and Necrotizing Glomerulonephritis Without Glomerular Immune Deposits: Report of Two Cases. <i>American Journal of Kidney Diseases</i> , 1991, 18, 257-263.	1.9	3
83	Tubulointerstitial Nephritis during the Heterologous Phase of Nephrotoxic Serum Nephritis. <i>Nephron</i> , 1991, 59, 304-313.	1.8	8
84	Localization of clusterin in the epimembranous deposits of passive Heymann nephritis. <i>Kidney International</i> , 1991, 39, 247-252.	5.2	27
85	Pathogenesis of interstitial fibrosis in chronic purine aminonucleoside nephrosis. <i>Kidney International</i> , 1991, 40, 1020-1031.	5.2	132
86	A study by immunofluorescence microscopy of the NC1 domain of collagen type IV in glomerular basement membranes of two patients with hereditary nephritis. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1990, 416, 205-212.	1.4	6
87	Intraglomerular leukocyte recruitment during nephrotoxic serum nephritis in rats. <i>Clinical Immunology and Immunopathology</i> , 1990, 57, 441-458.	2.0	11
88	Prolongation of acute renal failure in two patients with hemolytic-uremic syndrome due to excessive plasma infusion therapy. <i>Pediatric Nephrology</i> , 1989, 3, 420-423.	1.7	18
89	Acute tubulointerstitial nephritis associated with aminonucleoside nephrosis. <i>Kidney International</i> , 1988, 33, 14-23.	5.2	111
90	Demonstration by Light Microscopy of Cytomegalovirus on a Renal Biopsy of a Renal Allograft Recipient: Confirmation by Immunohistochemistry and in situ Hybridization. <i>Nephron</i> , 1987, 47, 205-208.	1.8	20

#	ARTICLE	IF	CITATIONS
91	Pseudohermaphroditism, glomerulopathy, and Wilms tumor (Drash syndrome): Frequency in end-stage renal failure. <i>Journal of Pediatrics</i> , 1985, 106, 584-587.	1.8	88
92	Decreased plasma fibronectin levels in children with hemolytic-uremic syndrome. <i>American Journal of Medicine</i> , 1985, 78, 549-554.	1.5	11
93	The distribution of the CR3 receptor on human cells and tissue as revealed by a monoclonal antibody. <i>Clinical Immunology and Immunopathology</i> , 1984, 31, 371-389.	2.0	52